<p>Nebula Research &amp; Development LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免费报告) 的股份增加了 82.4%。该基金在此期间购买了额外的 31,570 股后，持有该公司 69,884 股股票。Nebula Research &amp; Development LLC 在最近一个季度末持有 Kiniksa Pharmaceuticals International 0.09% 的股份，价值 1,934,000 美元。</p>
<p>其他一些机构投资者最近也对该股票的持仓进行了调整。Nuveen LLC 在第一季度获得了 Kiniksa Pharmaceuticals International 的新股份，价值约为 16,992,000 美元。Arrowstreet Capital Limited Partnership 在第二季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值约为 20,349,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 277.8%。Qube Research &amp; Technologies Ltd 现在持有 888,364 股该公司的股票，价值 24,581,000 美元，此前在此期间又购买了 653,236 股。Acadian Asset Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 170.3%。Acadian Asset Management LLC 现在持有 1,034,321 股该公司的股票，价值 22,961,000 美元，此前在上个季度又购买了 651,700 股。最后，AQR Capital Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 149.1%。AQR Capital Management LLC 现在持有 491,761 股该公司的股票，价值 10,922,000 美元，此前在上个季度又购买了 294,319 股。机构投资者持有该公司 53.95% 的股票。</p>
<h2>Kiniksa Pharmaceuticals International 的内部交易</h2>
<p>在相关消息中，首席财务官 Mark Ragosa 于 12 月 8 日星期一出售了 42,841 股 Kiniksa Pharmaceuticals International 的股票。股票以平均价格 41.49 美元出售，总价值为 1,777,473.09 美元。出售完成后，首席财务官持有 31,086 股该公司的股票，价值约为 1,289,758.14 美元。这笔交易代表其持仓减少了 57.95%。该交易在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，首席运营官 Eben Tessari 于 11 月 17 日星期一出售了 12,470 股该公司的股票。股票以平均价格 41.24 美元出售，总交易额为 514,262.80 美元。出售后，首席运营官持有 22,714 股该公司的股票，价值 936,725.36 美元。这笔交易代表其持仓减少了 35.44%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 537,280 股公司股票，价值 20,844,046 美元。公司内部人士持有该公司 53.48% 的股票。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些研究公司最近对 KNSA 发表了评论。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Kiniksa Pharmaceuticals International 股票的 &#34;持有 (c)&#34; 评级。Wells Fargo &amp; Company 将 Kiniksa Pharmaceuticals International 股票的目标价从 42.00 美元上调至 45.00 美元，并在 9 月 25 日星期四的研究报告中给予该公司 &#34;超配&#34; 评级。Zacks Research 在 10 月 6 日星期一的报告中将 Kiniksa Pharmaceuticals International 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Wedbush 在 12 月 2 日星期二的研究报告中重新发布了 &#34;跑赢大盘&#34; 评级，并对 Kiniksa Pharmaceuticals International 的股票设定了 48.00 美元的价格目标。最后，高盛集团在 10 月 29 日星期三的研究报告中将 Kiniksa Pharmaceuticals International 的目标价从 45.00 美元上调至 55.00 美元，并给予该公司 &#34;买入&#34; 评级。六位研究分析师对该股票给予了买入评级，两位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 52.00 美元。</p>
<p><strong>查看我们关于 Kiniksa Pharmaceuticals International 的最新研究报告</strong></p>
<h2>Kiniksa Pharmaceuticals International 股票上涨 1.2%</h2>
<p>KNSA 周五开盘价为 41.01 美元。该公司的 50 日移动平均价格为 39.78 美元，200 日移动平均价格为 34.33 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低价为 17.82 美元，1 年最高价为 42.98 美元。该公司的市值为 31.1 亿美元，市盈率为 91.14，贝塔值为 0.02。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 10 月 28 日星期二发布了其财报。该公司报告本季度每股收益为 0.23 美元，低于共识预期的 0.31 美元，差距为 0.08 美元。Kiniksa Pharmaceuticals International 的净利润率为 6.01%，股本回报率为 7.46%。该公司本季度的收入为 1.8086 亿美元，而分析师预期为 1.6664 亿美元。在去年同期，该公司的每股收益为 -0.18 美元。该公司的季度收入同比增长 61.2%。研究分析师平均预测 Kiniksa Pharmaceuticals International, plc 本财年将发布 -0.55 美元的每股收益。</p>
<h2>Kiniksa Pharmaceuticals International 简介</h2>
<p>(免费报告)</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，旨在为全球面临重大未满足医疗需求的虚弱疾病患者提供帮助。其产品候选药物包括 ARCALYST，一种针对复发性心包炎的白介素-1α和白介素-1β，复发性心包炎是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，目前正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 T 细胞共刺激信号，对于 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应至关重要。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>2026 年应避免的 3 只最近被下调评级的股票</li>
<li>恒生指数是什么？</li>
<li>芯片热潮回归：3 只有望大幅上涨的股票</li>
<li>3 只引领迷因股票复兴的股票</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Kiniksa Pharmaceuticals International 吗？</h2>
<p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
<p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KNSA

<p>Nebula Research & Development LLC 在第二季度将其在 Kiniksa Pharmaceuticals 的股份增加了 82.4%，持有 69,884 股，价值 193 万美元。其他机构投资者也调整了他们的持仓。内部交易包括首席财务官 Mark Ragosa 和首席运营官 Eben Tessari 的大量股票出售。分析师的评级意见不一，普遍目标价为 52.00 美元。Kiniksa 的股票目前交易价格为 41.01 美元，市值为 31.1 亿美元</p>

<p>Nebula Research &amp; Development LLC raised its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 82.4% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 69,884 shares of the company's stock after purchasing an additional 31,570 shares during the period. Nebula Research &amp; Development LLC owned 0.09% of Kiniksa Pharmaceuticals International worth $1,934,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Nebula Research &amp; Development LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免费报告) 的股份增加了 82.4%。该基金在此期间购买了额外的 31,570 股后，持有该公司 69,884 股股票。Nebula Research &amp; Development LLC 在最近一个季度末持有 Kiniksa Pharmaceuticals International 0.09% 的股份，价值 1,934,000 美元。</p>
</div><p>A number of other institutional investors have also recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $16,992,000. Arrowstreet Capital Limited Partnership bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $20,349,000. Qube Research &amp; Technologies Ltd increased its position in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period. Acadian Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after purchasing an additional 294,319 shares during the last quarter. Institutional investors own 53.95% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也对该股票的持仓进行了调整。Nuveen LLC 在第一季度获得了 Kiniksa Pharmaceuticals International 的新股份，价值约为 16,992,000 美元。Arrowstreet Capital Limited Partnership 在第二季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值约为 20,349,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 277.8%。Qube Research &amp; Technologies Ltd 现在持有 888,364 股该公司的股票，价值 24,581,000 美元，此前在此期间又购买了 653,236 股。Acadian Asset Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 170.3%。Acadian Asset Management LLC 现在持有 1,034,321 股该公司的股票，价值 22,961,000 美元，此前在上个季度又购买了 651,700 股。最后，AQR Capital Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 149.1%。AQR Capital Management LLC 现在持有 491,761 股该公司的股票，价值 10,922,000 美元，此前在上个季度又购买了 294,319 股。机构投资者持有该公司 53.95% 的股票。</p>
</div><h2>Insider Transactions at Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的内部交易</h2>
</div><p>In related news, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares of the company's stock, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,470 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.24, for a total transaction of $514,262.80. Following the sale, the chief operating officer owned 22,714 shares of the company's stock, valued at $936,725.36. This trade represents a 35.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 537,280 shares of company stock valued at $20,844,046. Company insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Mark Ragosa 于 12 月 8 日星期一出售了 42,841 股 Kiniksa Pharmaceuticals International 的股票。股票以平均价格 41.49 美元出售，总价值为 1,777,473.09 美元。出售完成后，首席财务官持有 31,086 股该公司的股票，价值约为 1,289,758.14 美元。这笔交易代表其持仓减少了 57.95%。该交易在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，首席运营官 Eben Tessari 于 11 月 17 日星期一出售了 12,470 股该公司的股票。股票以平均价格 41.24 美元出售，总交易额为 514,262.80 美元。出售后，首席运营官持有 22,714 股该公司的股票，价值 936,725.36 美元。这笔交易代表其持仓减少了 35.44%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 537,280 股公司股票，价值 20,844,046 美元。公司内部人士持有该公司 53.48% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of research firms have recently commented on KNSA. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wells Fargo &amp; Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 25th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Wedbush reissued an &#34;outperform&#34; rating and issued a $48.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $52.00.</p>
<div class="lb-trans"><p>一些研究公司最近对 KNSA 发表了评论。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Kiniksa Pharmaceuticals International 股票的 &#34;持有 (c)&#34; 评级。Wells Fargo &amp; Company 将 Kiniksa Pharmaceuticals International 股票的目标价从 42.00 美元上调至 45.00 美元，并在 9 月 25 日星期四的研究报告中给予该公司 &#34;超配&#34; 评级。Zacks Research 在 10 月 6 日星期一的报告中将 Kiniksa Pharmaceuticals International 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Wedbush 在 12 月 2 日星期二的研究报告中重新发布了 &#34;跑赢大盘&#34; 评级，并对 Kiniksa Pharmaceuticals International 的股票设定了 48.00 美元的价格目标。最后，高盛集团在 10 月 29 日星期三的研究报告中将 Kiniksa Pharmaceuticals International 的目标价从 45.00 美元上调至 55.00 美元，并给予该公司 &#34;买入&#34; 评级。六位研究分析师对该股票给予了买入评级，两位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 52.00 美元。</p>
</div><p><strong>View Our Latest Research Report on Kiniksa Pharmaceuticals International</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Kiniksa Pharmaceuticals International 的最新研究报告</strong></p>
</div><h2>Kiniksa Pharmaceuticals International Trading Up 1.2%</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票上涨 1.2%</h2>
</div><p>KNSA opened at $41.01 on Friday. The company has a fifty day moving average price of $39.78 and a two-hundred day moving average price of $34.33. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The company has a market cap of $3.11 billion, a P/E ratio of 91.14 and a beta of 0.02.</p>
<div class="lb-trans"><p>KNSA 周五开盘价为 41.01 美元。该公司的 50 日移动平均价格为 39.78 美元，200 日移动平均价格为 34.33 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低价为 17.82 美元，1 年最高价为 42.98 美元。该公司的市值为 31.1 亿美元，市盈率为 91.14，贝塔值为 0.02。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The business's quarterly revenue was up 61.2% on a year-over-year basis. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 10 月 28 日星期二发布了其财报。该公司报告本季度每股收益为 0.23 美元，低于共识预期的 0.31 美元，差距为 0.08 美元。Kiniksa Pharmaceuticals International 的净利润率为 6.01%，股本回报率为 7.46%。该公司本季度的收入为 1.8086 亿美元，而分析师预期为 1.6664 亿美元。在去年同期，该公司的每股收益为 -0.18 美元。该公司的季度收入同比增长 61.2%。研究分析师平均预测 Kiniksa Pharmaceuticals International, plc 本财年将发布 -0.55 美元的每股收益。</p>
</div><h2>Kiniksa Pharmaceuticals International Profile</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，旨在为全球面临重大未满足医疗需求的虚弱疾病患者提供帮助。其产品候选药物包括 ARCALYST，一种针对复发性心包炎的白介素-1α和白介素-1β，复发性心包炎是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，目前正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 T 细胞共刺激信号，对于 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应至关重要。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>What is the Hang Seng index?</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>2026 年应避免的 3 只最近被下调评级的股票</li>
<li>恒生指数是什么？</li>
<li>芯片热潮回归：3 只有望大幅上涨的股票</li>
<li>3 只引领迷因股票复兴的股票</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Kiniksa Pharmaceuticals International 吗？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nebula Research & Development LLC 持有 Kiniksa Pharmaceuticals International, plc 价值 193 万美元的股份